AI Brain Health Leader Omniscient Closes Series C Funding Round
Summary
This represents the most recent milestone in the companys history of continued growth, with two FDA-cleared products to date.At the intersection of data science and neuroscience, the company stands as a global pioneer in connectomics, utilizing AI to map and analyze an individuals intricate web of brain connections and functions.Among Omniscients investors are prominent Australian business leaders Will Vicars and Gina Rinehart, underscoring their continued confidence in Omniscients vision and capabilities. This latest achievement follows Omniscients successful participation at the 2024 South By Southwest\xae (SXSW) conference in Austin, Texas, where the company showcased its transformative impact on brain health and human potential.Omniscient will utilize the funds to expand its presence in the US market where more than 100 US hospitals and clinics utilize the companys AI-enabled connectomic analysis platform, Quicktome\xae and to advance product development efforts targeting expanded indications.At Omniscient, we create meaningful AI-driven technologies that are transforming how we understand and care for the brain. Omniscient recently expanded its product offering to include the first FDA-cleared neurological planning and visualization tool using resting-state fMRI, opening up new horizons for Quicktome in areas such as stroke, disorders of consciousness, and oncology. We are an artificial intelligence innovation hub that creates advanced technologies to conquer the problems and enhance the potential of the human brain for the benefit of all humankind. Today, Omniscients connectomics AI platform, Quicktome\xae, provides critical insights informing prognosis and planning across neurologic conditions, from cranial surgery and neuro-oncology to stroke and beyond.